HomeBUSINESS
BUSINESS

JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
(Oct.30.2017)

Japan Tobacco signed an exclusive agreement with its subsidiary Torii Pharmaceutical to jointly develop and commercialize JTZ-951, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed by JT for the treatment of renal anemia ...
(LOG IN FOR FULL STORY)

News Calendar